NEWS BIOCON

1.

Biocon adds heft to research services arm

Syngene works with 16 of the top 20 pharma companies across the globe
As Biocon holds back the public listing of its research services arm, Syngene, the
company is strengthening the division by aggressively pursuing global majors to
build a larger, attractive clientele and a bigger workforce. Syngene International
Ltd, a subsidiary of Biocon, tied up with Baxter International Inc, a US-based
pharmaceutical company to jointly establish a research centre within the Syngene
premises in Bangalore.
2.

Biocon Q3 net up 14 per cent at Rs 104.99 crore...

Bangalore-based biotech major Biocon Ltd today reported 14.41 per cent increase
in its consolidated net profit for the third quarter ended December 31, 2013 at Rs
104.99 crore. The company had posted a consolidated net profit of Rs 91.76 crore
in the same quarter last fiscal. Consolidated net sales during the quarter under
review stood at Rs 701.16 crore as against Rs 634.22 crore in the year-ago period.
3. Biocon's Kiran Mazumdar-Shaw to receive 2014

Othmer Gold
Bio-tech firm Biocon Ltd today said its Chairperson and Managing Director Kiran
Mazumdar - Shaw, will be conferred the 2014 Othmer Gold Medal, the top award
of US-based Chemical Heritage Foundation.

4. Biocon inks pact with Advaxis for novel cancer

immunotherapy 'ADXS-HPV'
Biocon and Advaxis Inc., a leader in the next generation of cancer
immunotherapies have entered into an exclusive licensing agreement for codevelopment and commercialization of ADXS-HPV, a novel cancer
immunotherapy for the treatment of human papillomavirus (HPV)-associated
cervical cancer in women, for India and key emerging markets.